The company said worldwide revenues for the 3-month period ended March 31, 2024 rose 4.6% from the prior-year period to $5.045 billion.

1. 01

   The company said worldwide revenues for the 3-month period ended March 31, 2024 rose 4.6% from the prior-year period to $5.045 billion.

2. 02

   Cash flows from continuing operating activities were $1.369 billion in the first 6 months of fiscal 2024, the company said, and it paid cash dividends to common shareholders of $550 million over the same period.

3. 03

   BD said market dynamics in China, such as volume-based procurement programs (VoBP), had an adverse impact on its results, particularly in the Medical segment. It also said labor costs in Q2 were generally higher than in the prior-year period.

4. 04

   BD has a 5-year senior unsecured revolving credit facility providing borrowings of up to $2.750 billion, the company said, and there were no borrowings outstanding under the facility or commercial paper as of March 31, 2024.

Key figures

Quarter ended March 31, 2024

Revenue

$5.0B

Operating income

$734M

Net income

$537M

EPS

$1.85

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.